vs
Side-by-side financial comparison of ALAMO GROUP INC (ALG) and Apellis Pharmaceuticals, Inc. (APLS). Click either name above to swap in a different company.
ALAMO GROUP INC is the larger business by last-quarter revenue ($373.6M vs $199.9M, roughly 1.9× Apellis Pharmaceuticals, Inc.). ALAMO GROUP INC runs the higher net margin — 4.2% vs -29.5%, a 33.6% gap on every dollar of revenue. On growth, ALAMO GROUP INC posted the faster year-over-year revenue change (-3.0% vs -5.9%). ALAMO GROUP INC produced more free cash flow last quarter ($69.9M vs $-14.3M). Over the past eight quarters, Apellis Pharmaceuticals, Inc.'s revenue compounded faster (7.7% CAGR vs -6.3%).
The Alamo Drafthouse Cinema is an American cinema chain founded in 1997 in Austin, Texas, which is famous for serving dinner and drinks during the film, as well as its strict policy of requiring its audiences to maintain proper cinema-going etiquette. Sony Pictures Experiences acquired the chain in June 2024.
Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies that modulate the complement system to address serious unmet medical needs. Its core products target ophthalmic conditions like geographic atrophy secondary to age-related macular degeneration, as well as rare hematological and autoimmune disorders, with primary operations in the United States and European markets.
ALG vs APLS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $373.6M | $199.9M |
| Net Profit | $15.5M | $-59.0M |
| Gross Margin | 22.7% | — |
| Operating Margin | 6.0% | -25.6% |
| Net Margin | 4.2% | -29.5% |
| Revenue YoY | -3.0% | -5.9% |
| Net Profit YoY | -44.8% | -62.2% |
| EPS (diluted) | $1.28 | $-0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $373.6M | $199.9M | ||
| Q3 25 | $420.0M | $458.6M | ||
| Q2 25 | $419.1M | $178.5M | ||
| Q1 25 | $390.9M | $166.8M | ||
| Q4 24 | $385.3M | $212.5M | ||
| Q3 24 | $401.3M | $196.8M | ||
| Q2 24 | $416.3M | $199.7M | ||
| Q1 24 | $425.6M | $172.3M |
| Q4 25 | $15.5M | $-59.0M | ||
| Q3 25 | $25.4M | $215.7M | ||
| Q2 25 | $31.1M | $-42.2M | ||
| Q1 25 | $31.8M | $-92.2M | ||
| Q4 24 | $28.1M | $-36.4M | ||
| Q3 24 | $27.4M | $-57.4M | ||
| Q2 24 | $28.3M | $-37.7M | ||
| Q1 24 | $32.1M | $-66.4M |
| Q4 25 | 22.7% | — | ||
| Q3 25 | 24.2% | — | ||
| Q2 25 | 25.8% | — | ||
| Q1 25 | 26.3% | — | ||
| Q4 24 | 23.8% | — | ||
| Q3 24 | 25.1% | — | ||
| Q2 24 | 26.0% | — | ||
| Q1 24 | 26.2% | — |
| Q4 25 | 6.0% | -25.6% | ||
| Q3 25 | 8.9% | 48.7% | ||
| Q2 25 | 11.2% | -18.6% | ||
| Q1 25 | 11.4% | -50.0% | ||
| Q4 24 | 8.9% | -12.3% | ||
| Q3 24 | 10.0% | -24.0% | ||
| Q2 24 | 10.4% | -14.7% | ||
| Q1 24 | 11.0% | -36.0% |
| Q4 25 | 4.2% | -29.5% | ||
| Q3 25 | 6.0% | 47.0% | ||
| Q2 25 | 7.4% | -23.6% | ||
| Q1 25 | 8.1% | -55.3% | ||
| Q4 24 | 7.3% | -17.1% | ||
| Q3 24 | 6.8% | -29.2% | ||
| Q2 24 | 6.8% | -18.9% | ||
| Q1 24 | 7.5% | -38.5% |
| Q4 25 | $1.28 | $-0.40 | ||
| Q3 25 | $2.10 | $1.67 | ||
| Q2 25 | $2.57 | $-0.33 | ||
| Q1 25 | $2.64 | $-0.74 | ||
| Q4 24 | $2.33 | $-0.30 | ||
| Q3 24 | $2.28 | $-0.46 | ||
| Q2 24 | $2.35 | $-0.30 | ||
| Q1 24 | $2.67 | $-0.54 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $309.7M | $466.2M |
| Total DebtLower is stronger | $190.7M | — |
| Stockholders' EquityBook value | $1.1B | $370.1M |
| Total Assets | $1.6B | $1.1B |
| Debt / EquityLower = less leverage | 0.17× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $309.7M | $466.2M | ||
| Q3 25 | $244.8M | $479.2M | ||
| Q2 25 | $201.8M | $370.0M | ||
| Q1 25 | $200.3M | $358.4M | ||
| Q4 24 | $197.3M | $411.3M | ||
| Q3 24 | $140.0M | $396.9M | ||
| Q2 24 | $118.5M | $360.1M | ||
| Q1 24 | $121.8M | $325.9M |
| Q4 25 | $190.7M | — | ||
| Q3 25 | $194.4M | — | ||
| Q2 25 | $198.1M | — | ||
| Q1 25 | $201.8M | — | ||
| Q4 24 | $205.5M | — | ||
| Q3 24 | $209.2M | — | ||
| Q2 24 | $278.6M | — | ||
| Q1 24 | $306.5M | $93.1M |
| Q4 25 | $1.1B | $370.1M | ||
| Q3 25 | $1.1B | $401.2M | ||
| Q2 25 | $1.1B | $156.3M | ||
| Q1 25 | $1.1B | $164.2M | ||
| Q4 24 | $1.0B | $228.5M | ||
| Q3 24 | $1.0B | $237.1M | ||
| Q2 24 | $979.7M | $264.3M | ||
| Q1 24 | $956.6M | $266.7M |
| Q4 25 | $1.6B | $1.1B | ||
| Q3 25 | $1.6B | $1.1B | ||
| Q2 25 | $1.6B | $821.4M | ||
| Q1 25 | $1.5B | $807.3M | ||
| Q4 24 | $1.5B | $885.1M | ||
| Q3 24 | $1.5B | $901.9M | ||
| Q2 24 | $1.5B | $904.5M | ||
| Q1 24 | $1.5B | $831.9M |
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | 0.19× | — | ||
| Q4 24 | 0.20× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.32× | 0.35× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.1M | $-14.2M |
| Free Cash FlowOCF − Capex | $69.9M | $-14.3M |
| FCF MarginFCF / Revenue | 18.7% | -7.1% |
| Capex IntensityCapex / Revenue | 1.4% | 0.1% |
| Cash ConversionOCF / Net Profit | 4.84× | — |
| TTM Free Cash FlowTrailing 4 quarters | $146.9M | $45.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.1M | $-14.2M | ||
| Q3 25 | $65.5M | $108.5M | ||
| Q2 25 | $22.7M | $4.4M | ||
| Q1 25 | $14.2M | $-53.4M | ||
| Q4 24 | $79.1M | $19.4M | ||
| Q3 24 | $96.3M | $34.1M | ||
| Q2 24 | $33.2M | $-8.3M | ||
| Q1 24 | $1.1M | $-133.0M |
| Q4 25 | $69.9M | $-14.3M | ||
| Q3 25 | $53.1M | $108.3M | ||
| Q2 25 | $15.7M | $4.4M | ||
| Q1 25 | $8.2M | $-53.4M | ||
| Q4 24 | $73.1M | $19.3M | ||
| Q3 24 | $88.4M | — | ||
| Q2 24 | $28.8M | $-8.4M | ||
| Q1 24 | $-5.5M | $-133.3M |
| Q4 25 | 18.7% | -7.1% | ||
| Q3 25 | 12.6% | 23.6% | ||
| Q2 25 | 3.8% | 2.5% | ||
| Q1 25 | 2.1% | -32.0% | ||
| Q4 24 | 19.0% | 9.1% | ||
| Q3 24 | 22.0% | — | ||
| Q2 24 | 6.9% | -4.2% | ||
| Q1 24 | -1.3% | -77.3% |
| Q4 25 | 1.4% | 0.1% | ||
| Q3 25 | 3.0% | 0.0% | ||
| Q2 25 | 1.7% | 0.0% | ||
| Q1 25 | 1.5% | 0.0% | ||
| Q4 24 | 1.6% | 0.0% | ||
| Q3 24 | 2.0% | 0.0% | ||
| Q2 24 | 1.1% | 0.0% | ||
| Q1 24 | 1.6% | 0.2% |
| Q4 25 | 4.84× | — | ||
| Q3 25 | 2.58× | 0.50× | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 2.82× | — | ||
| Q3 24 | 3.51× | — | ||
| Q2 24 | 1.17× | — | ||
| Q1 24 | 0.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALG
| Wholegood Units | $293.2M | 78% |
| Parts | $61.6M | 16% |
| Other Revenue | $18.9M | 5% |
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
